Malicon

Citalopram, the active ingredient in Malicon, is a selective serotonin reuptake inhibitor (SSRI) presented as a tablet for oral use. It is prescribed to treat major depressive disorder and related anxiety conditions in adults.

GNH USA supplies Malicon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Citalopram, an SSRI that modulates serotonergic pathways, is indicated for several mood and anxiety disorders.

- Major depressive disorder: alleviates depressive symptoms and improves overall mood. - Obsessive‑compulsive disorder: reduces intrusive thoughts and compulsive behaviors. - Panic disorder: decreases the frequency and severity of panic attacks. - Social anxiety disorder: lessens anxiety in social situations.

Citalopram may cause a range of adverse reactions, some of which are frequent while others are uncommon but serious.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient tension‑type headaches. - Dry mouth: reduced salivary flow. - Insomnia: difficulty falling or staying asleep.

Serious or Rare Side Effects: - Serotonin syndrome: potentially life‑threatening condition with agitation, hyperthermia, and neuromuscular abnormalities. - QT interval prolongation: may predispose to cardiac arrhythmias. - Suicidal thoughts: especially in younger adults during early treatment.

When prescribing or dispensing Citalopram, several safety considerations should be observed.

- Assess psychiatric history: monitor for worsening depression or emergent suicidal ideation. - Review cardiac history: consider baseline ECG for patients at risk of QT prolongation. - Avoid abrupt discontinuation: taper under medical supervision to prevent discontinuation syndrome. - Use caution in pregnancy: classified as Category B; discuss potential risks with the prescriber. - Store at room temperature: keep in the original pack, protect from moisture and light.

Citalopram can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of serotonin syndrome. - Other serotonergic agents (e.g., tramadol, triptans): increased serotonin toxicity. - CYP2C19 inhibitors (e.g., omeprazole): may raise citalopram plasma levels.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., carbamazepine): may reduce therapeutic effect. - Anticoagulants (e.g., warfarin): potential for enhanced bleeding. - NSAIDs: may increase gastrointestinal bleeding risk.